Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

The association between the Arg280His polymorphism in the XRCC1 gene and the risk of hematological malignancies

Authors: Xiang Tong, Jiqiao Yang, Yuanling Peng, Jiani Shen, Tianyuan Xiong, Yonggang Zhang, Hong Fan

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

The associations between the Arg280His polymorphism in X-ray repair cross-complementing gene 1 (XRCC1 gene) and hematological malignancies have been extensively investigated. However, the results were inconsistent. The objective of the current study was to investigate the associations between the Arg280His polymorphism in XRCC1 gene and the risk of hematological malignancies by meta-analysis. We searched PubMed, Embase, CNKI, Wanfang, and Weipu databases, covering all studies until 07 Aug 2013. Statistical analysis was performed by using the Revman4.2 software and the Stata10.0 software. A total of 2,650 cases and 3,856 controls in 12 case–control studies concerning the Arg280His polymorphism were included. The results suggested that the Arg280His polymorphism might not be associated with risk of hematological malignancies (OR = 1.08, 95%CI = 0.86–1.35, P = 0.50). In the subgroup analyses by cancer types and ethnicity, no significant associations were found among different cancers or different ethnicities. The current meta-analysis indicated that the Arg280His polymorphism in the XRCC1 gene might not be a risk factor for hematological malignancies. In future, more large-scale case–control studies are needed to validate these results.
Literature
1.
2.
Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA: J Am Med Assoc. 2011;306(17):1874–83. doi:10.​1001/​jama.​2011.​1558.CrossRef
3.
Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. New England J Med. 2013;368(19):1771–80. doi:10.​1056/​NEJMoa1212772.CrossRef
4.
Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850):1309–16. doi:10.​1016/​S0140-6736(12)60689-8.PubMedCrossRef
5.
Ganster C, Neesen J, Zehetmayer S, Jager U, Esterbauer H, Mannhalter C, et al. DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2009;48(9):760–7. doi:10.​1002/​gcc.​20680.PubMedCrossRef
6.
7.
8.
Li J (2011) Association of XRCC1 polymorphis with leukemia susceptibility in northwest Chinese population.
9.
10.
Zhang Y, Wang Y, Wu J, Li LJ. XRCC1 Arg194Trp polymorphism is associated with oral cancer risk: evidence from a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(4):2321–7. doi:10.​1007/​s13277-013-0779-y.CrossRef
11.
Shen M, Purdue MP, Kricker A, Lan Q, Grulich AE, Vajdic CM, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin’s lymphoma in New South Wales, Australia. Haematologica. 2007;92(9):1180–5.PubMedCrossRef
12.
13.
Meza-Espinoza JP, Peralta-Leal V, Gutierrez-Angulo M, Macias-Gomez N, Ayala-Madrigal ML, Barros-Nunez P, et al. XRCC1 polymorphisms and haplotypes in Mexican patients with acute lymphoblastic leukemia. Genet Mol Res: GMR. 2009;8(4):1451–8. doi:10.​4238/​vol8-4gmr687.PubMedCrossRef
14.
Zhao W, Luo J, Cai X. Association between microsomal epoxide hydrolase 1 polymorphisms and susceptibility to esophageal cancer: a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(4):2383–8. doi:10.​1007/​s13277-013-0787-y.CrossRef
15.
Chen W, Zhao H, Li T, Yao H. HFE gene C282Y variant is associated with colorectal cancer in Caucasians: a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(4):2255–9. doi:10.​1007/​s13277-013-0766-3.CrossRef
16.
17.
Pakakasama S, Sirirat T, Kanchanachumpol S, Udomsubpayakul U, Mahasirimongkol S, Kitpoka P, et al. Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia. Pediatric Blood Cancer. 2007;48(1):16–20. doi:10.​1002/​pbc.​20742.PubMedCrossRef
18.
Ren LJ, Zhang QH, Shi JY, Zhang QL, Jiang XX, Hou SL, et al. Polymorphisms of DNA repair genes XRCC1 and susceptibility to non-Hodgkin lymphoma. Baixuebing He Linbaliu. 2009;18(4):197–200.
19.
Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, Roos G, Ryder LP, Falk KI, Palmgren J, Kere J, Melbye M, Glimelius B, Adami HO (2006) Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 15 (2):258–265. doi:10.​1158/​1055-9965.​EPI-05-0583
20.
Zhu R, Wu Y, Lu FJ, Wang AH, Tang JY, Zhao JC, et al. Polymorphisms and haplotypes of XRCC1 and APE1 and risk of childhood leukaemia in China: a case–control analysis. Eur J Oncol. 2008;13(3):187–92.
Metadata
Title
The association between the Arg280His polymorphism in the XRCC1 gene and the risk of hematological malignancies
Authors
Xiang Tong
Jiqiao Yang
Yuanling Peng
Jiani Shen
Tianyuan Xiong
Yonggang Zhang
Hong Fan
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1232-y

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue

Research Article

Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition

Research Article

Quantitative assessment of the influence of tumor necrosis factor alpha polymorphism with gastritis and gastric cancer risk

Erratum

Erratum to: Prognostication of OCT4 isoform expression in prostate cancer

Research Article

The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells

Research Article

Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics

Research Article

Quantitative assessment of the association between XRCC3 C18607T polymorphism and glioma risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits